FDA approves Wegovy-like GLP-1 pill, Foundayo, for weight loss
This image was generated by AI and may not depict real events.
The FDA has approved Eli Lilly's Foundayo, a once-daily oral GLP-1 receptor agonist, for weight loss in adults with obesity or overweight with weight-related medical problems. This approval makes Foundayo the second GLP-1 drug available in pill form, offering a non-injectable option for weight management.
The FDA has approved Foundayo, a once-daily oral GLP-1 receptor agonist, for weight loss. Foundayo is the second GLP-1 drug available in pill form. It offers a non-injectable option for weight management. Clinical data shows that participants taking Foundayo achieved meaningful weight loss. Foundayo can be taken any time of day without food or water restrictions, improving adherence for some individuals. The approval was expedited through the FDA's National Priority Voucher program.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.